Office Of New Drug Chemistry Reorganization Creates "PALS" For Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's restructuring of the Office of New Drug Chemistry includes adding dedicated chemistry, manufacturing and controls reviewers within the premarketing and postmarketing divisions
You may also be interested in...
FDA CMC Pilot Program: More NDA Data, Less Inspectional Oversight
FDA is seeking 12 original NDAs ready for submission by the end of 2006 for a pilot program that will reshape the kind of information included in the chemistry, manufacturing and controls section of applications. Manufacturing would be governed more by “process understanding” and less by standard operating procedures, FDA says.
Product Quality Research Institute Will Help Implement FDA’s CMC Regulatory Paradigm
PQRI will help reshape the agency’s CMC regulatory paradigm to match the advancements in manufacturing science. The institute also plans to explore postapproval changes for aseptic processes.
Product Quality Research Institute Will Help Implement FDA’s CMC Regulatory Paradigm
PQRI will help reshape the agency’s CMC regulatory paradigm to match the advancements in manufacturing science. The institute also plans to explore postapproval changes for aseptic processes.